vaginitis--%20trichomoniasis,%20candidiasis,%20bacterial%20vaginosis
VAGINITIS: TRICHOMONIASIS, CANDIDIASIS, BACTERIAL VAGINOSIS

Trichomoniasis is caused by a flagellated protozoan, Trichomonas vaginalis. It is always sexually transmitted.

Bacterial vaginosis is the most common cause of vaginitis, vaginal discharge or malodor. Its prevalence is similar in both pregnant and non-pregnant women.

Vulvovaginal candidiasis is caused by overgrowth of yeasts where 70-90% of cases are secondary to Candida albicans. It most commonly occurs when the vagina is exposed to estrogen (ie, reproductive years, pregnancy) and may be precipitated by antibiotic or corticosteroid use. Immunocompromised and diabetic women are also at risk.

Drug Information

Indication: Relief of external thrush symptoms.

Indication: Infections of genital region (vaginitis) caused by fungi (usually Candida) & superinfections caused by Clo...

Indication: Dermatophytes or yeasts, mycoses & other fungi eg, Tinea capitis, corporis, manuum, barbae, cruris, pedis....

Endix
econazole nitrate + triamcinolone acetonide

Indication: Dermatophytosis: Tinea pedis, tinea corporis, tinea capitis, tinea cruris, tinea barbae. Tinea versicolor, can...

Indication: Vulvovag mycosis & mycotic balanitis.

Indication: Topical treatment of dermatophyte skin infections eg, tinea corporis, cruris, manus & pedis due to Trichop...

Pevisone
econazole nitrate + triamcinolone acetonide

Indication: Dermatomycoses complicated by inflammatory &/or pruritic manifestations of skin disorders.

Indication: Cap: Vulvovag & oral candidosis; dermatomycosis, plantar tinea pedis & palmar tinea manus, pityriasis ...

Indication: Local treatment of inflammation or infection & tissue damage of vag & cervix (eg, discharge due to bac...

1  /  11
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 14 Dec 2016

The addition of ibandronate to adjuvant hormonal therapy provides no benefit to postmenopausal women with HR-positive breast cancer, according to early results from the phase III TEAM IIB trial (BOOG 2006-4)*.